Drug Profile
Research programme: complement factor 5a inhibitors - Jerini
Alternative Names: JPE-1375; JSM-1375; JSM-7717Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Jerini
- Developer Jerini; Jerini Ophthalmic
- Class Small molecules
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Inflammation
Most Recent Events
- 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations for a variety of ophthalmic indications, including JPE 1375 for age-related macular degeneration
- 09 Nov 2007 JSM 7717 and JPE 1375 are available for partnering for renal therapy (http://www.jerini.com)
- 09 Nov 2007 JPE 1375 is available for licensing (http://www.jophth.com)